アブストラクト
| Title | 心腎貧血症候群 |
|---|---|
| Subtitle | 特集 心腎連関から新薬まで! 心×腎疾患の薬物治療 心腎連関を考慮した薬物治療 |
| Authors | 常喜信彦, 原田美奈子 |
| Authors (kana) | |
| Organization | 東邦大学医療センター大橋病院腎臓内科 |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 4 |
| Page | 721-725 |
| Year/Month | 2022 / 3 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points]●慢性的な貧血は高心拍出性心不全の原因となりうる. ●心腎貧血症候群(CRAS)は, 心不全, 腎不全, 貧血がお互いに影響を及ぼし, 悪循環を形成していることを指す一病態である. ●CRASから, 鉄欠乏の状態も加わった心腎貧血鉄欠乏症候群(CRAIDS)に移行している. 腎性貧血治療の第一歩は, 鉄の補充を考慮することから始まる. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Koury ST, et al : Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization : correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood, 74 : 645-651, 1989
- 2) Donnelly S : Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis, 38 : 415-425, 2001
- 3) 日本透析医学会 : 2015年版 慢性腎臓病患者における腎性貧血治療のガイドライン. 日本透析医学会雑誌, 49 : pp89-158, 2016
- 4) McCullough PA : Anemia of cardiorenal syndrome. Kidney Int Suppl(2011), 11 : 35-45, 2021
- 5) Sofue T, et al : Prevalence of anemia in patients with chronic kidney disease in Japan : A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database(J-CKD-DB). PLoS One, 15 : e0236132, 2020
残りの12件を表示する
- 6) van der Meer P, et al : Mitochondrial function, skeletal muscle metabolism, and iron deficiency in heart failure. Circulation, 139 : 2399-2402, 2019
- 7) Okonko DO, et al : Disordered iron homeostasis in chronic heart failure : prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol, 58 : 1241-1251, 2011
- 8) Melenovsky V, et al : Myocardial iron content and mitochondrial function in human heart failure : a direct tissue analysis. Eur J Heart Fail, 19 : 522-530, 2017
- 9) Alnuwaysir RIS, et al : Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome : findings from the BIOSTAT-CHF study. Eur J Heart Fail, 24 : 192-204, 2022
- 10) Klip IT, et al : The additive burden of iron deficiency in the cardiorenal-anaemia axis : scope of a problem and its consequences. Eur J Heart Fail, 16 : 655-662, 2014
- 11) Lewis GD, et al : Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency : The IRONOUT HF randomized clinical trial. JAMA, 317 : 1958-1966, 2017
- 12) Swedberg K, et al : Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med, 368 : 1210-1219, 2013
- 13) Saaby L, et al : Classification of myocardial infarction : frequency and features of type 2 myocardial infarction. Am J Med, 126 : 789-797, 2013
- 14) Heerspink HJL, et al : Dapagliflozin in patients with chronic kidney disease. N Engl J Med, 383 : 1436-1446, 2020
- 15) Chertow GM, et al : Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol, 32 : 2352-2361, 2021
- 16) Oshima M, et al : Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease : a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol, 8 : 903-914, 2020
- 17) Mazer CD, et al : Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation, 141 : 704-707, 2020
